NGLY1 and mantle cell lymphoma: Interestingly, Tomlin et al reported the development of a small molecule inhibitor of NGLY1 that enhanced cytotoxicity of the proteasome inhibitor bortezomib used to treat the mature B-cell malignancies multiple myeloma and mantle cell lymphoma 103.